Chemotherapy, immunotherapy, biologic therapy, investigational therapy, or hormonal therapy within 28 days or five half-lives of a drug (whichever is longer) prior to the first dose of pazopanib. [clinicaltrials_resource:24aef00c1c2b0429e845d38987da4f4b]
inclusion criteria [clinicaltrials_vocabulary:inclusion-criteria]
Chemotherapy, immunotherapy, biologic therapy, investigational therapy, or hormonal therapy within 28 days or five half-lives of a drug (whichever is longer) prior to the first dose of pazopanib. [clinicaltrials_resource:24aef00c1c2b0429e845d38987da4f4b]
Bio2RDF identifier
24aef00c1c2b0429e845d38987da4f4b
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:24aef00c1c2b0429e845d38987da4f4b
identifier
clinicaltrials_resource:24aef00c1c2b0429e845d38987da4f4b
title
Chemotherapy, immunotherapy, b ...... o the first dose of pazopanib.
@en
type
label
Chemotherapy, immunotherapy, b ...... ef00c1c2b0429e845d38987da4f4b]
@en